Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Mylan launches tablets...

    Mylan launches tablets for treatment of Hepatitis C in India

    Written by Ruby Khatun Khatun Published On 2017-07-28T09:30:03+05:30  |  Updated On 28 July 2017 9:30 AM IST
    Mylan launches tablets for treatment of Hepatitis C in India

    HERTFORDSHIRE, England and PITTSBURGH: Mylan Pharmaceuticals Private Limited (a subsidiary of Mylan N.V.) announced the launch of Velpatasvir 100 mg/Sofosbuvir 400 mg Tablets under the brand name MyHep All™ in India.


    MyHep All™ is a fixed-dose combination tablet indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, including all six major HCV genotypes.


    A Velpatasvir 100 mg /Sofosbuvir 400 mg combination product is currently sold by Gilead Sciences in other markets under the brand name EPCLUSA®.


    HCV is a bloodborne virus commonly transmitted through unsafe injection practices, inadequate sterilization of medical equipment, and the transfusion of unscreened blood and blood products. HCV also can be transmitted sexually and can be passed from an infected mother to her baby.


    HCV can cause both acute and chronic infections. Approximately 55–85% of those infected will develop chronic HCV infection. People with chronic HCV infection are often undiagnosed because the infection can remain asymptomatic for decades. In many instances, symptoms develop because of serious liver damage.


    It's estimated that more than 70 million people around the world have chronic hepatitis C infection, and nearly 400,000 people die each year from hepatitis C-related liver diseases.


    "Chronic hepatitis C is a significant public health burden in India. When we launched Mylan's Hepato Care division in January 2015, we did so to increase access to critical, life-saving medicines for patients with chronic HCV and other liver-related conditions," commented Mylan President Rajiv Malik. "The launch of the fixed-dose combination of MyHep All™ is part of this mission and will help patients adhere to their chronic HCV treatment regimen. Mylan has a longstanding, ongoing commitment to accelerate access and to improve treatment outcomes in India and other developing countries."


    The MyHepAll™ launch follows Mylan's successful January 2016 launch of MyHep LVIR™ (Ledipasvir/Sofosbuvir combination) in India.


    Mylan has the non-exclusive right to manufacture and distribute Velpatasvir/Sofosbuvir in approximately 100 developing countries via a license agreement from Gilead Sciences.

    EpclusaGilead Scienceshepatitis CHepatitis C VirusIndiaLaunchMyHep AllMylanRajiv MaliksofosbuvirTabletsVelpatasvir
    Source : PRESS RELEASE

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok